This site is intended for health professionals only
Saturday 23 June 2018
Share |

Topic: breast cancer

May 4, 2018
Herzuma is the third biosimilar to be marketed and distributed by the Mundipharma network in Europe

The Mundipharma global network of independent associated companies has announced that Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months.

The Mundipharma network has exclusive distribution rights to Herzuma
in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.

March 8, 2018
Ontruzant is the first breast cancer biosimilar to be launched in the UK, and is the first product approved in the UK under a global biosimilars development and commercialisation agreement between MSD and Samsung Bioepis Co Ltd

MSD has announced the launch of Ontruzant®, (trastuzumab), a biosimilar referencing Herceptin® (trastuzumab/TRZ), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

This was the first trastuzumab biosimilar to receive regulatory approval in Europe and is the first to launch in the UK.1

February 15, 2018
Herzuma® (CT-P6) granted EU marketing authorisation to treat early breast cancer, metastatic breast cancer and metastatic gastric cancer

Celltrion Healthcare has announced that the European Commission (EC) has approved Herzuma® (trastuzumab biosimilar, CT-P6) for all indications of reference trastuzumab in the European Union (EU).

The approval of Herzuma® marks the third Celltrion Healthcare product approved in the EU and builds on the company’s expanding biosimilar portfolio.

November 16, 2017
Fulvestrant in combination with palbociclib showed progression-free survival improvement of 4.9 months compared to combination of fulvestrant with placebo

AstraZeneca has announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.1

August 24, 2017
Ribociclib in combination with an aromatase inhibitor is a new and effective treatment option offering postmenopausal women with the most common form of advanced breast cancer the possibility of two years without disease progression

Novartis has announced that Kisqali®(ribociclib) has received authorisation from the European Commission for the treatment of advanced breast cancer. Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.

September 26, 2016
Study finds 57% relative increase in breast cancer detection in dense breast tissue when ABUS used together with mammography

The European Asymptomatic Screening Study (EASY) aimed to evaluate the impact of ABUS in conjunction with full field digital screening mammography (FFDSM) in 1668 women aged 40–74 with dense breasts. The study showed a 57 %1 relative increase in breast cancer detection in dense breast tissue, or 6.6 cancers detected per 1000 women screened, compared with 4.2 cancers per 1000 women for mammography alone. 2

October 1, 2015
At this year's European Society of Breast Imaging (EUSOBI) Congress, GE Healthcare provides a new supplementary screening exam option; Invenia™ Automated Breast Ultrasound System (ABUS)

With an estimated 494,000 new cases per year, breast cancer is by far the most common cancer among women across Europe. Particularly affected are women with dense breast tissue because of the difficultly it can cause when trying to detect cancer early using mammography. At this year's European Society of Breast Imaging (EUSOBI) Congress, GE Healthcare provides a new supplementary screening exam option; Invenia™ Automated Breast Ultrasound System (ABUS) – that can be used to increase cancer detection sensitivity in dense breast tissue.
 

September 30, 2015
Additional clinical outcomes from large patient registry confirm accuracy of Oncotype DX test in guiding treatment decisions
September 29, 2015
Perjeta (pertuzumab) regimen nearly doubled number of women whose tumours are eradicated versus standard treatment

Over 1800 women per year in the UK with an aggressive type of breast cancer could benefit from Perjeta (pertuzumab) as a targeted neo-adjuvant (pre-surgery) treatment for HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. Perjeta is licensed for use in combination with current treatment Herceptin® (trastuzumab) and chemotherapy.
 

July 1, 2015
Planmed introduces a new mammography unit, which utilises advanced Digital Breast Tomosynthesis (DBT) technology. DBT enables enhanced diagnostics, especially for patients with denser breast tissue

Digital Breast Tomosynthesis resolves the challenge of overlapping tissue structures by producing a 3D volume of the breast. As a whole, Planmed Clarity 3D enables sharp reconstructions with a higher visibility of microcalcifications and delicate tissue structures through its patented Continuous Sync-and-Shoot™ method. This new approach to tomosynthesis imaging eliminates motion blur and artefact intrusion, ensuring that small calcifications and blood vessels can be seen with clarity.

October 3, 2014
Three out of four people are not aware that dense breast tissue increases a woman’s risk of developing breast cancer, according to a new global study from GE Healthcare exploring perspectives on breast cancer with an emphasis on understanding awareness around dense breast tissue and the most common symptoms of breast cancer.

Three out of four people are not aware that dense breast tissue increases a woman’s risk of developing breast cancer, (1,2) according to a new global study from GE Healthcare exploring perspectives on breast cancer with an emphasis on understanding awareness around dense breast tissue and the most common symptoms of breast cancer.

August 8, 2012
Correct classification of breast density is essential, and the rise of digital mammography means that more quantitative measurements are now possible
Chantal van Ongeval MD PhD
Radiology Department, 
University Hospitals Leuven, 
Belgium
Breast cancer is the most common cancer in women. Mammography is the only imaging technique that has been proven to reduce breast cancer mortality. The sensitivity of mammography for a nearly fatty breast is approximately 80%; for a dense breast, however, sensitivity is reduced to 40%. 
September 16, 2009
US scientists have discovered that breast cancer tumours can be shrunk more quickly when a common diabetes treatment is added to chemotherapy

US scientists have discovered that breast cancer tumours can be shrunk more quickly when a common diabetes treatment is added to chemotherapy.

Researchers discovered that the drug metformin appeared to target breast cancer stem cells – which are resistant to conventional therapy – in mice, raising hopes of a more effective means of treating the disease in humans.

November 12, 2008
Bristol hospital pioneers a revolutionary new way of scanning breast cancer patients

A hospital in Bristol is pioneering a revolutionary way of scanning for breast cancer that is quicker and safer than conventional methods.

The world's first radar breast-imaging system takes approximately six minutes to operate, compared with up to 45 minutes for an MRI.

The device, developed by Bristol University, uses radio waves that offer no risk from radiation, unlike conventional mammograms.

The system has been used at Frenchay Hospital since September, with around 60 women having been examined using the technology.

October 24, 2008
A hospital in Manchester will be the first to use new high-tech system for detecting breast cancer

A hospital in Greater Manchester is set to become the first in the UK to use a new high-tech system for detecting breast cancer.

Computer-aided detection (CAD) is the technology behind the MAMMOMAT Inspiration Full-Field Direct Digital Mammography system, from Siemens Healthcare.

Stepping Hill Hospital in Stockport, part of the Stockport NHS Foundation Trust, has ordered two of the units which will help radiologists to interpret digital breast images by flagging up areas of possible concern.

August 22, 2008
Newly published NHS figures show cancer patients are still waiting too long for hospital treatment

Cancer patients in Scotland are still having to wait too long for hospital treatment, according to newly-published NHS figures.

In 2001 a target was set for 95% of cancer patients to be treated within 62 days of urgent referral by 2005. However, that target has never been achieved, and the latest figures show that the health service is still falling short.

Across Scotland, 94.1% of patients were treated within 62 days, compared with 93.6% in the previous quarter.

January 18, 2008
The National Institute for Clinical Excellence (NICE) guidelines on follow-up for breast cancer patients need urgent revision, warn experts in this week’s British Medical Journal.

The National Institute for Clinical Excellence (NICE) guidelines on follow-up for breast cancer patients need urgent revision, warn experts in this week’s British Medical Journal.

More than 1.2 million women and men worldwide are diagnosed with breast cancer each year and it is now recognised as a chronic disease that can recur even after 20–30 years.

December 17, 2007
A report into how a breast cancer patient in the Republic of Ireland was incorrectly given the all-clear by a hospital has been delayed, it has emerged

A report into how a breast cancer patient in the Republic of Ireland was incorrectly given the all-clear by a hospital has been delayed, it has emerged.

Rebecca O'Malley underwent a fine needle biopsy in Limerick in March 2005, and the results from Cork University Hospital (CUH) said the sample was benign.

But later the 41-year-old from Co Tipperary suffered pain in her breast and a second biopsy confirmed she had cancer. She then had to have a mastectomy and intensive chemotherapy.